{"transactions":[{"id":1869425,"issuer":{"id":5813,"kind":"organization","name":"DiaMedica Therapeutics Inc."},"owners":[{"id":112802,"kind":"person","name":"Daves Julie VanOrsdel","position":1,"cik":"0001945603","reported_name":"Daves Julie VanOrsdel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development Oper."}}],"security":"Stock Option (right to buy)","published_at":"2023-06-02T21:16:33.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":54000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests with respect to 25% of the underlying common shares on June 1, 2024 and with respect to the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2024."}],"balance_after":54000,"derivative":{"exercise_price":2.73,"expiration_date":"2033-05-31","underlying":"Common Shares","underlying_shares":54000},"source":{"system":"sec-edgar","filing":"0001235802-23-000065","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1401040/000123580223000065/primary_doc.xml","form_type":"4"}},{"id":2158328,"issuer":{"id":5813,"kind":"organization","name":"DiaMedica Therapeutics Inc."},"owners":[{"id":112802,"kind":"person","name":"Daves Julie VanOrsdel","position":1,"cik":"0001945603","reported_name":"Daves Julie VanOrsdel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development Oper."}}],"security":"Stock Option  (right to buy)","published_at":"2022-09-15T20:41:28.000Z","date":"2022-09-13","kind":"grant","acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests with respect to 35,000 common shares on September 13, 2023 and with respect to the remaining 75% of the common shares in 36 nearly equal monthly installments commencing one month after the one-year anniversary of the grant date."}],"balance_after":140000,"derivative":{"exercise_price":1.47,"expiration_date":"2032-09-12","underlying":"Common Shares","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001235802-22-000111","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1401040/000123580222000111/primary_doc.xml","form_type":"4"}}]}